Clinical trial
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine…
NCT00380367 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00380367 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) |
| Official title | Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Papillomavirus Infections |
| Intervention type | Biological |
| Interventions | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine |
| Enrollment | 110 |
| Start date | May 3, 2007 |
| Primary completion | Feb 4, 2008 |
| Completion | Feb 4, 2008 |
| First posted | Sep 26, 2006 |
| Last update posted | May 31, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: